DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Custirsen is an investigational drug.
There have been 12 clinical trials for Custirsen. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2010.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Lung Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are OncoGenex Technologies, NCIC Clinical Trials Group, and Teva Pharmaceutical Industries.
Recent Clinical Trials for Custirsen
|Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization||Teva Pharmaceutical Industries||Phase 1|
|Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization||OncoGenex Technologies||Phase 1|
|A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer||OncoGenex Technologies||Phase 3|